Leading biotech company Theralase Technologies ($TLT:CA) ($TLTFF) has announced the completion of a detailed reporting of just how its TLC-3000B Laser System will be used in the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).
Cold Laser Therapy or Low Level Laser Therapy (LLLT) utilizes specific frequencies of light to interact with human tissue to aid in healing and reduce inflammation. Non-thermal photons can pass through layers of skin to effect the muscles or other tissue underneath directly, making the technology important for pain relief in treating injuries.
Theralase has led the way in developing this technology and developing new uses. This includes its Photo Dynamic Therapy (PDT) products, which can be used in a variety of oncological purposes.
How Theralase’s Laser System Treats NMIBC
The new detailed report shows how clinicians can use the TLC-3000B Laser System to activate Theralase’s lead light activated Photo Dynamic Compound (PDC), TLD-1433, to treat NMIBC. The plan will now await approval from the University Health Network’s (UHN) Review Ethics Board (REB), which is expected in Q4 of 2015. With that approval, Theralase is planning on moving forward with a Phase Ib clinical study to test the efficacy of the new plan.
The company has now completed the four key components necessary for submitting an REB to the UHN: GMP manufacture of the drug, a Good Laboratory Practice toxicology analysis, finishing of the Clinical Protocol and Investigators Brochure, and the completion of the detailed information they announced today.
“The completion of the fourth and final component required to submit a REB to UHN and a CTA to Health Canada marks a new milestone in Theralase’s pursuit of the destruction of NMIBC,” said Roger Domoulin-White, Theralase’s President and CEO. “Pending approval of these two submissions, Theralase will commence enrolling and treating patients in a Phase Ib clinical study for NMIBC at UHN.”
Moving forward with this new treatment is part of a two-pronged strategy enacted by the company. First, they are currently developing uses for LLLTs that have application both in cancer treatment and pain relief. In conjunction, they are building a biopharma company that can capitalize on their patented PDT technology.
Disclosure: In the purview of Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention the fact that Equities.com, Inc. may be compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker, broker dealer, investment advisor, analyst, investment banker or underwriter. All profiles are based on information that is available to the public. The information contained herein should not be considered to be all-inclusive and is not guaranteed by Equities.com to be free from misstatement or errors. Readers are reminded to do their own due diligence when researching any companies mentioned on this website.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer